VGX-1027

• CAT Number: I004453
• CAS Number: 6501-72-0
• Molecular Formula: C11H11NO3
• Molecular Weight: 205.2
• Purity: ≥95%
• Target: immunomodulator
• Solubility: DMSO: ≥ 56 mg/mL
• Storage: 2-8°C
• IUPAC Name: 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
• InChI: InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)
• InChIKey: MUFJHYRCIHHATF-UHFFFAOYSA-N
• SMILES: C1C(ON=C1C2=CC=CC=C2)CC(=O)O

VGX-1027（Cat No.:I004453）, also known as GIT27, is an isoxazole compound with potent immunomodulatory properties. This compound has been shown to reduce the secretion of inflammatory cytokines, such as IL-1beta, TNF-alpha, and IL-10, from purified murine macrophages. By modulating the immune response, VGX-1027 has the potential to regulate inflammation and immune-mediated diseases. Its ability to inhibit cytokine production suggests its potential as a therapeutic agent for conditions characterized by excessive inflammation.

Reference

1:Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects. Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, Bagarazzi ML, Muthumani K, Boyer J, Agarwal V, Nicoletti F, Bart S, Kim JJ, Weiner DB, Sardesai NY.Clin Pharmacol Drug Dev. 2016 Mar;5(2):91-101. doi: 10.1002/cpdd.193. Epub 2015 Jun 8. PMID: 27138022 2:VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. Fagone P, Muthumani K, Mangano K, Magro G, Meroni PL, Kim JJ, Sardesai NY, Weiner DB, Nicoletti F.Immunology. 2014 Aug;142(4):594-602. doi: 10.1111/imm.12267. PMID: 24527796 Free PMC Article3:Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Mangano K, Sardesai NY, Quattrocchi C, Mazzon E, Cuzzocrea S, Bendtzen K, Meroni PL, Kim JJ, Nicoletti F.Br J Pharmacol. 2008 Nov;155(5):722-30. doi: 10.1038/bjp.2008.315. Epub 2008 Sep 8. PMID: 18776919 Free PMC Article4:In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Mangano K, Sardesai N, D/’Alcamo M, Libra M, Malaguarnera L, Donia M, Bendtzen K, Meroni P, Nicoletti F.Eur J Pharmacol. 2008 May 31;586(1-3):313-21. doi: 10.1016/j.ejphar.2008.02.017. Epub 2008 Feb 17. PMID: 18374912 5:In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, Donia M, Al Abed Y, Kim J, Nicoletti F, Stosic-Grujicic S, Claesson M.Clin Immunol. 2007 Jun;123(3):311-23. Epub 2007 Apr 20. PMID: 17449326